Europe Blood-based Biomarker For Parkinson’s Disease Market Size & Outlook

The blood-based biomarker for parkinson’s disease market in Europe is expected to reach a projected revenue of US$ 97.5 million by 2033. A compound annual growth rate of 11.9% is expected of Europe blood-based biomarker for parkinson’s disease market from 2025 to 2033.
Revenue, 2024 (US$M)
$32.1
Forecast, 2033 (US$M)
$97.5
CAGR, 2025 - 2033
11.9%
Report Coverage
Europe

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Europe blood-based biomarker for parkinson’s disease market, 2021-2033 (US$M)

Europe blood-based biomarker for parkinson’s disease market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Europe blood-based biomarker for parkinson’s disease market highlights

  • The Europe blood-based biomarker for parkinson’s disease market generated a revenue of USD 32.1 million in 2024.
  • The market is expected to grow at a CAGR of 11.9% from 2025 to 2033.
  • In terms of segment, protein biomarkers was the largest revenue generating biomarker type in 2024.
  • Protein Biomarkers is the most lucrative biomarker type segment registering the fastest growth during the forecast period.


Europe data book summary

Market revenue in 2024USD 32.1 million
Market revenue in 2033USD 97.5 million
Growth rate11.9% (CAGR from 2025 to 2033)
Largest segmentProtein biomarkers
Fastest growing segmentProtein Biomarkers
Historical data covered2021 - 2023
Base year for estimation2024
Forecast period covered2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationProtein Biomarkers


Other key industry trends

  • In terms of revenue, Europe region accounted for 27.2% of the global blood-based biomarker for parkinson’s disease market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2033.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 83.3 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Blood-based Biomarker For Parkinson’s Disease Market Companies

Name Profile # Employees HQ Website
Acobiom View profile 1-10 Grabels, Languedoc-Roussillon, France, Europe http://www.acobiom.com/en/
Banyan Biomarkers View profile 11-50 Alachua, Florida, United States, North America http://banyanbio.com
Alseres Pharmaceuticals View profile 1-10 Hopkinton, Massachusetts, United States, North America http://www.alseres.com
Quanterix View profile 251-500 Billerica, Massachusetts, United States, North America http://www.quanterix.com
Johnson & Johnson Services, Inc. View profile - - -
Abbott View profile - - -
Rules-Based Medicine a Q Squared Solutions Company View profile 51-100 Austin, Texas, United States, North America http://rbm.q2labsolutions.com
DiaGenic View profile 11-50 Oslo, Oslo, Norway, Europe http://www.diagenic.com/
Qiagen NV View profile 5900 Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL https://www.qiagen.com
Bio-Rad Laboratories Inc View profile 8030 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 https://www.bio-rad.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com
Merck KGaA View profile 62345 Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 https://www.emdgroup.com

Europe blood-based biomarker for parkinson’s disease market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood-based biomarker for parkinson’s disease market will help companies and investors design strategic landscapes.


Protein biomarkers was the largest segment with a revenue share of 123.68% in 2024. Horizon Databook has segmented the Europe blood-based biomarker for parkinson’s disease market based on protein biomarkers covering the revenue growth of each sub-segment from 2021 to 2033.


Reasons to subscribe to Europe blood-based biomarker for parkinson’s disease market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe blood-based biomarker for parkinson’s disease market databook

  • Our clientele includes a mix of blood-based biomarker for parkinson’s disease market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe blood-based biomarker for parkinson’s disease market , including forecasts for subscribers. This continent databook contains high-level insights into Europe blood-based biomarker for parkinson’s disease market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online